Related Experiment Video

Updated: Jun 23, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

New developments in the antiviral treatment of hepatitis C

J de Bruijne1, C J Weegink, P L M Jansen

  • 1AMC Liver Center, Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. j.debruijne@amc.nl

Vox Sanguinis
|April 28, 2009
PubMed

Insights

Chronic hepatitis C virus (HCV) infection causes significant liver disease globally. New antiviral therapies show promise for improved treatment outcomes and shorter durations compared to current interferon and ribavirin regimens.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Chronic hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis and hepatocellular carcinoma worldwide.
  • HCV affects 170 million people globally, with HCV-related end-stage liver disease being a primary indication for liver transplantation in Western countries.
  • Current treatment with pegylated interferon and ribavirin has variable efficacy (40-80%) and significant side effects.

Purpose of the Study:

  • To review the latest advancements in antiviral therapy for chronic hepatitis C.
  • To discuss the development and evaluation of new specifically targeted antiviral therapies for hepatitis C (STAT-C).
  • To highlight promising new antiviral agents and their potential impact on treatment duration and outcomes.

Main Methods:

  • Review of recent clinical trials evaluating new antiviral agents for HCV.
  • Analysis of data from in vitro culture systems that have accelerated antiviral research.
  • Assessment of the efficacy and safety profiles of emerging STAT-C treatments.

Main Results:

  • Development of reliable in vitro culture systems has significantly advanced HCV research.
  • Numerous new STAT-C agents are under clinical evaluation.
  • These novel therapies are anticipated to enhance treatment effectiveness and potentially shorten treatment duration.

Conclusions:

  • New antiviral therapies are expected to revolutionize hepatitis C treatment.
  • Improved efficacy and reduced side effects are anticipated with STAT-C.
  • Further research and clinical trials are crucial to identify the most effective treatment strategies.

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Related Concept Videos

Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...